AbbVie Reports Third-Quarter 2024 Financial Highlights
AbbVie (NYSE: ABBV) has reported its financial results for the third quarter of the fiscal year 2024. These results reflect the company's commitment to delivering strong performance across its diverse portfolio of products.
Financial Performance Overview
For the third quarter of 2024, AbbVie recorded a diluted GAAP earnings per share (EPS) of $0.88. Meanwhile, the adjusted diluted EPS increased to $3.00, marking a rise of 1.7% compared to the previous year. These results, however, were impacted by an unfavorable expense of $0.04 per share from acquired IPR&D and milestones.
The total net revenues for the quarter reached $14.460 billion, showing an increase of 3.8% on a reported basis and 4.9% on an operational basis. This growth was notably supported by the performance of AbbVie's various product portfolios.
Immunology Portfolio Insights
The immunology portfolio generated global net revenues of $7.046 billion, reflecting an increase of 3.9% on a reported basis. Within this segment, Humira faced a decline, bringing in $2.227 billion, a drop of 37.2%. Contrarily, Skyrizi shined with revenues of $3.205 billion, up 50.8%, while Rinvoq contributed $1.614 billion, showing a growth of 45.3%.
Oncology and Neuroscience Growth
In the oncology division, AbbVie’s products yielded $1.687 billion, marking an impressive rise of 11.6%. Sales from Imbruvica reached $828 million, although it represented a decrease. The Venclexta drug saw an increase, contributing $677 million.
In neuroscience, AbbVie reported revenues of $2.363 billion, a robust increase of 15.6%. Botox Therapeutic achieved sales of $848 million, and Vraylar brought in $875 million.
Strategic Moves and Future Outlook
AbbVie has further fortified its market position by successfully completing the acquisition of Cerevel, enhancing its neuroscience portfolio. This acquisition adds promising assets including emraclidine, tavapadon, and CVL-354, all showing potential to significantly impact future revenues.
Additionally, AbbVie has raised its full-year 2024 adjusted diluted EPS guidance, now projecting a range of $10.90 to $10.94. This guidance anticipates an unfavorable effect from IPR&D expenses accumulated throughout the year.
Dividend Declaration
In a commitment to its shareholders, AbbVie has announced a 5.8% dividend increase, raising the quarterly cash dividend from $1.55 to $1.64 per share, effective from February 2025.
Key Company Information
AbbVie is dedicated to discovering and providing innovative treatments addressing significant health challenges across major therapeutic areas, including immunology, oncology, and neuroscience. Stay informed by visiting AbbVie’s official website.
Frequently Asked Questions
What were AbbVie's diluted earnings per share (EPS) for Q3 2024?
AbbVie reported a diluted EPS of $0.88 on a GAAP basis and $3.00 on an adjusted basis for Q3 2024.
What are the major product portfolios that AbbVie focuses on?
AbbVie’s major product portfolios include immunology, oncology, neuroscience, and aesthetics.
How did AbbVie's neuroscience portfolio perform in Q3 2024?
The neuroscience portfolio generated $2.363 billion in global net revenues, representing a growth of 15.6% compared to the previous year.
What was the increase in AbbVie's quarterly dividend for 2025?
The quarterly cash dividend was increased by 5.8%, from $1.55 to $1.64 per share.
Why did AbbVie lower its guidance for Humira?
Humira’s revenues decreased by 37.2% due to market competition and the transition to new treatments like Skyrizi and Rinvoq, impacting overall performance.
